Clinicohematological profile and treatment outcomes of Hodgkin’s Lymphoma- a single center experience from Pakistan.
DOI:
https://doi.org/10.29309/TPMJ/2026.33.03.9528Keywords:
Clinico-hematological Characteristics, Hodgkin’s Lymphoma (HL), Overall Survival, TreatmentAbstract
Objective: To evaluate the epidemiological and clinical characteristics, along with treatment outcomes of Hodgkin’s lymphoma patients in Pakistan. Study Design: Prospective Cross Sectional study. Setting: National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Pakistan. Period: January to December 2024. Methods: This was a cross sectional study comprising 22 patients diagnosed with HL as per WHO Classification who presented at National Institute of Blood Diseases and BMT Karachi Pakistan from January to December 2024. The quantitative variables were represented as mean (SD), while nominal variables were presented as frequency and percentages by using SPSS 25 version and STATA 15 version. The Kaplan Meier analysis and log rank test was done for survival analysis. Results: A total of 22 HL patients were included in the study. The mean age of the study participants was 31.7±18.7 years. In the study, 63.6% of the patients were male, while 36.4% were female. B symptoms were present in 86.4% of the patients. Hepatomegaly, was noted in 27.3, while splenomegaly, was observed in 45.5% of patients. The Hb level in the cohort was above 10.5 g/dl in the majority (63.7%), while 36.3% had anemia. LDH is a marker of tissue damage, and in this cohort, 63.7% of patients had LDH levels higher than 220 U/L, indicating ongoing cellular breakdown or tissue damage. The site of tissue diagnosis in the study primarily involved cervical lymph nodes (72.8%), followed by Axillary (13.7%) and inguinal (9.1%) lymph nodes. The 90 months overall survival in 22 patients was 73.5%. Conclusion: The present study revealed the detailed clinical hematological and treatment outcome of HL patients in Pakistan. However, multicenter studies with larger sample size are needed to validate the findings and enhance treatment strategy especially for relapse patients.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 The Professional Medical Journal

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.